FBXO22 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that blocks the activity of the proteasome complex, leading to the accumulation of polyubiquitinated proteins and inhibition of protein degradation. By preventing the degradation of FBXO22 and its substrates, MG-132 effectively inhibits the function of FBXO22 and its downstream cellular processes. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is a potent inhibitor of NEDD8-activating enzyme (NAE), which inhibits neddylation, a post-translational modification essential for the activation of Cullin-RING ubiquitin ligases (CRLs) including SCF (Skp1-Cullin1-F-box) complexes. | ||||||
CDC25 Phosphatase Inhibitor II, NSC 663284 | 383907-43-5 | sc-202987A sc-202987 sc-202987B sc-202987C | 1 mg 5 mg 10 mg 25 mg | $51.00 $241.00 $357.00 $663.00 | 4 | |
NSC 663284 is a small molecule inhibitor of casein kinase 2 (CK2), which phosphorylates FBXO22 and regulates its stability and activity. Inhibition of CK2 by NSC 663284 disrupts FBXO22 phosphorylation and may lead to its destabilization or altered function, thereby inhibiting FBXO22-mediated ubiquitination and degradation of its substrates. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343 is a selective inhibitor of enhancer of zeste homolog 1 (EZH1) and EZH2, components of the polycomb repressive complex 2 (PRC2) involved in histone methylation and gene silencing. Inhibition of EZH1/2 by GSK343 may modulate the epigenetic regulation of FBXO22 and its target genes, impacting FBXO22-mediated cellular processes. | ||||||
Dihydro Artemisinin | 71939-50-9 | sc-211332 | 100 mg | $233.00 | 1 | |
Dihydro Artemisinin is a derivative of artemisinin, a natural compound with anti-malarial properties. Recent studies have shown that dihydroartemisinin inhibits the proliferation and induces apoptosis in cancer cells by downregulating the expression of FBXO22 and its downstream targets involved in cell cycle progression and apoptosis regulation. | ||||||
Thymoquinone | 490-91-5 | sc-215986 sc-215986A | 1 g 5 g | $47.00 $133.00 | 21 | |
Thymoquinone is a bioactive compound found in black seed oil with anticancer properties. Thymoquinone inhibits the expression of FBXO22 and its substrates involved in cell cycle regulation and apoptosis, leading to cell cycle arrest and apoptosis induction in cancer cells. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX795 is a selective inhibitor of TBK1 and IKKε, serine/threonine kinases involved in innate immune responses and inflammation. Inhibition of TBK1/IKKε by BX795 may modulate the NF-κB signaling pathway, which regulates the expression of FBXO22 and its substrates involved in cell cycle progression and inflammation, leading to inhibition of FBXO22-mediated cellular processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor approved for multiple myeloma. By inhibiting the proteasome, bortezomib blocks the degradation of FBXO22 and its substrates, leading to the accumulation of polyubiquitinated proteins and inhibition of FBXO22-mediated cellular processes such as cell cycle progression and apoptosis regulation. | ||||||